CA2671554A1

CA2671554A1 - Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition

Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition Download PDF

Info

Publication number: CA2671554A1
Authority: CA; Canada
Prior art keywords: compound; disorders; compounds; disorder; formula
Prior art date: 2007-01-10
Legal status : Abandoned

Application number

CA002671554A

Other languages

English (en)

French (fr)

Inventor

Josephus H. M. Lange

Cornelis G. Kruse

Current Assignee

Abbott Healthcare Products BV

Original Assignee

Individual

Priority date

2007-01-10

Filing date

2008-01-09

Publication date

2008-07-17

2008-01-09 Application filed by Individual filed Critical Individual

2008-07-17 Publication of CA2671554A1 publication Critical patent/CA2671554A1/en

Status Abandoned legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 148
230000000697 serotonin reuptake Effects 0.000 title claims abstract description 20
230000005764 inhibitory process Effects 0.000 title claims abstract description 12
230000008485 antagonism Effects 0.000 title claims description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
208000035475 disorder Diseases 0.000 claims abstract description 16
206010013663 drug dependence Diseases 0.000 claims abstract description 13
208000004296 neuralgia Diseases 0.000 claims abstract description 13
208000019901 Anxiety disease Diseases 0.000 claims abstract description 10
208000024827 Alzheimer disease Diseases 0.000 claims abstract description 9
208000008589 Obesity Diseases 0.000 claims abstract description 9
208000018737 Parkinson disease Diseases 0.000 claims abstract description 9
208000028017 Psychotic disease Diseases 0.000 claims abstract description 9
208000010877 cognitive disease Diseases 0.000 claims abstract description 9
208000021722 neuropathic pain Diseases 0.000 claims abstract description 9
235000020824 obesity Nutrition 0.000 claims abstract description 9
208000011117 substance-related disease Diseases 0.000 claims abstract description 9
208000012201 sexual and gender identity disease Diseases 0.000 claims abstract description 8
208000015891 sexual disease Diseases 0.000 claims abstract description 8
208000027520 Somatoform disease Diseases 0.000 claims abstract description 5
230000036506 anxiety Effects 0.000 claims abstract description 5
230000006735 deficit Effects 0.000 claims abstract description 5
208000027753 pain disease Diseases 0.000 claims abstract description 5
-1 V-24343 Chemical compound 0.000 claims description 63
150000003839 salts Chemical class 0.000 claims description 24
239000003814 drug Substances 0.000 claims description 22
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 22
229910052757 nitrogen Inorganic materials 0.000 claims description 21
125000004433 nitrogen atom Chemical group N* 0.000 claims description 20
102000009132 CB1 Cannabinoid Receptor Human genes 0.000 claims description 18
108010073366 CB1 Cannabinoid Receptor Proteins 0.000 claims description 18
239000004480 active ingredient Substances 0.000 claims description 18
229910052739 hydrogen Inorganic materials 0.000 claims description 16
239000001257 hydrogen Substances 0.000 claims description 15
239000012453 solvate Substances 0.000 claims description 15
150000001204 N-oxides Chemical class 0.000 claims description 14
239000012634 fragment Substances 0.000 claims description 14
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 12
125000005843 halogen group Chemical group 0.000 claims description 12
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 12
239000000651 prodrug Substances 0.000 claims description 11
229940002612 prodrug Drugs 0.000 claims description 11
125000001424 substituent group Chemical group 0.000 claims description 11
238000011282 treatment Methods 0.000 claims description 11
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
229940124802 CB1 antagonist Drugs 0.000 claims description 9
239000000126 substance Substances 0.000 claims description 9
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 8
208000019454 Feeding and Eating disease Diseases 0.000 claims description 8
208000006011 Stroke Diseases 0.000 claims description 8
206010047700 Vomiting Diseases 0.000 claims description 8
229960002464 fluoxetine Drugs 0.000 claims description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 8
125000001072 heteroaryl group Chemical group 0.000 claims description 7
229950002473 indalpine Drugs 0.000 claims description 7
SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 claims description 7
239000003112 inhibitor Substances 0.000 claims description 7
125000004430 oxygen atom Chemical group O* 0.000 claims description 7
229960002296 paroxetine Drugs 0.000 claims description 7
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims description 7
229960003015 rimonabant Drugs 0.000 claims description 7
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 6
125000004429 atom Chemical group 0.000 claims description 6
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 6
125000006125 ethylsulfonyl group Chemical group 0.000 claims description 6
125000004705 ethylthio group Chemical group C(C)S* 0.000 claims description 6
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 6
229960004038 fluvoxamine Drugs 0.000 claims description 6
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 6
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 6
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 6
125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims description 6
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
229920006395 saturated elastomer Polymers 0.000 claims description 6
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 5
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 5
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 5
229960001653 citalopram Drugs 0.000 claims description 5
206010015037 epilepsy Diseases 0.000 claims description 5
229960002073 sertraline Drugs 0.000 claims description 5
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 5
229960002791 zimeldine Drugs 0.000 claims description 5
OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 claims description 5
BSMNRYCSBFHEMQ-KCJUWKMLSA-N (1r,5s)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@]1(CNC2)[C@@H]2C1 BSMNRYCSBFHEMQ-KCJUWKMLSA-N 0.000 claims description 4
AXJQVVLKUYCICH-OAQYLSRUSA-N (4s)-5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C=1C=C(Cl)C=CC=1C([C@H](C1)C=2C=CC=CC=2)=NN1C(=NC)NS(=O)(=O)C1=CC=C(Cl)C=C1 AXJQVVLKUYCICH-OAQYLSRUSA-N 0.000 claims description 4
208000007848 Alcoholism Diseases 0.000 claims description 4
208000000103 Anorexia Nervosa Diseases 0.000 claims description 4
208000027559 Appetite disease Diseases 0.000 claims description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
208000020925 Bipolar disease Diseases 0.000 claims description 4
206010006550 Bulimia nervosa Diseases 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
208000024172 Cardiovascular disease Diseases 0.000 claims description 4
206010008120 Cerebral ischaemia Diseases 0.000 claims description 4
206010008190 Cerebrovascular accident Diseases 0.000 claims description 4
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 4
208000022497 Cocaine-Related disease Diseases 0.000 claims description 4
206010012289 Dementia Diseases 0.000 claims description 4
206010012335 Dependence Diseases 0.000 claims description 4
208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
206010012735 Diarrhoea Diseases 0.000 claims description 4
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 4
208000014094 Dystonic disease Diseases 0.000 claims description 4
208000030814 Eating disease Diseases 0.000 claims description 4
206010014612 Encephalitis viral Diseases 0.000 claims description 4
206010057671 Female sexual dysfunction Diseases 0.000 claims description 4
208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
208000011688 Generalised anxiety disease Diseases 0.000 claims description 4
208000010412 Glaucoma Diseases 0.000 claims description 4
206010019233 Headaches Diseases 0.000 claims description 4
208000023105 Huntington disease Diseases 0.000 claims description 4
208000030990 Impulse-control disease Diseases 0.000 claims description 4
206010061218 Inflammation Diseases 0.000 claims description 4
206010057672 Male sexual dysfunction Diseases 0.000 claims description 4
208000026139 Memory disease Diseases 0.000 claims description 4
208000019695 Migraine disease Diseases 0.000 claims description 4
208000008238 Muscle Spasticity Diseases 0.000 claims description 4
208000000112 Myalgia Diseases 0.000 claims description 4
206010028813 Nausea Diseases 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 4
208000036110 Neuroinflammatory disease Diseases 0.000 claims description 4
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
208000002193 Pain Diseases 0.000 claims description 4
206010036618 Premenstrual syndrome Diseases 0.000 claims description 4
208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims description 4
208000034189 Sclerosis Diseases 0.000 claims description 4
206010040070 Septic Shock Diseases 0.000 claims description 4
208000007107 Stomach Ulcer Diseases 0.000 claims description 4
208000000323 Tourette Syndrome Diseases 0.000 claims description 4
208000016620 Tourette disease Diseases 0.000 claims description 4
208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
206010044565 Tremor Diseases 0.000 claims description 4
206010046543 Urinary incontinence Diseases 0.000 claims description 4
201000007930 alcohol dependence Diseases 0.000 claims description 4
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
230000002490 cerebral effect Effects 0.000 claims description 4
238000002512 chemotherapy Methods 0.000 claims description 4
229960004606 clomipramine Drugs 0.000 claims description 4
201000006145 cocaine dependence Diseases 0.000 claims description 4
206010012601 diabetes mellitus Diseases 0.000 claims description 4
235000014632 disordered eating Nutrition 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
208000010118 dystonia Diseases 0.000 claims description 4
208000029364 generalized anxiety disease Diseases 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
231100000869 headache Toxicity 0.000 claims description 4
230000004054 inflammatory process Effects 0.000 claims description 4
208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
230000009245 menopause Effects 0.000 claims description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
206010027599 migraine Diseases 0.000 claims description 4
201000006417 multiple sclerosis Diseases 0.000 claims description 4
230000008693 nausea Effects 0.000 claims description 4
208000015122 neurodegenerative disease Diseases 0.000 claims description 4
201000008482 osteoarthritis Diseases 0.000 claims description 4
208000019906 panic disease Diseases 0.000 claims description 4
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 4
206010036596 premature ejaculation Diseases 0.000 claims description 4
208000026961 psychosexual disease Diseases 0.000 claims description 4
206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
201000000980 schizophrenia Diseases 0.000 claims description 4
230000036303 septic shock Effects 0.000 claims description 4
208000019116 sleep disease Diseases 0.000 claims description 4
208000020685 sleep-wake disease Diseases 0.000 claims description 4
208000020431 spinal cord injury Diseases 0.000 claims description 4
229940124597 therapeutic agent Drugs 0.000 claims description 4
230000009529 traumatic brain injury Effects 0.000 claims description 4
201000002498 viral encephalitis Diseases 0.000 claims description 4
KWDBQJRWPWTGPF-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-n-piperidin-1-ylpyrazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C)C(C(=O)NN2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl KWDBQJRWPWTGPF-UHFFFAOYSA-N 0.000 claims description 3
HMXDWDSNPRNUKI-UHFFFAOYSA-N 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-3-pyrazolecarboxamide Chemical compound CCC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Br)C=C1 HMXDWDSNPRNUKI-UHFFFAOYSA-N 0.000 claims description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
229960000836 amitriptyline Drugs 0.000 claims description 3
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 3
208000015114 central nervous system disease Diseases 0.000 claims description 3
125000001153 fluoro group Chemical group F* 0.000 claims description 3
150000004677 hydrates Chemical class 0.000 claims description 3
229960004801 imipramine Drugs 0.000 claims description 3
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 3
208000024714 major depressive disease Diseases 0.000 claims description 3
229960003991 trazodone Drugs 0.000 claims description 3
PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 3
DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 claims description 2
GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 2
UNAANXDKBXWMLN-INIZCTEOSA-N (1s)-1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1([C@@H](N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-INIZCTEOSA-N 0.000 claims description 2
BSMNRYCSBFHEMQ-GZMMTYOYSA-N (1s,5r)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@@]1(CNC2)[C@H]2C1 BSMNRYCSBFHEMQ-GZMMTYOYSA-N 0.000 claims description 2
HRNDUKHBCUTNAL-FERBBOLQSA-N (2s)-1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[[2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-benzofuran-4-yl]oxy]propan-2-ol;hydrochloride Chemical compound Cl.O1C(C)=NN=C1C(OC1=CC=C2)=CC1=C2OC[C@@H](O)CN1CCC(C=2C=C(Cl)C(Cl)=CC=2)CC1 HRNDUKHBCUTNAL-FERBBOLQSA-N 0.000 claims description 2
YCHYFHOSGQABSW-RTBURBONSA-N (6ar,10ar)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid Chemical compound C1C(C(O)=O)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 YCHYFHOSGQABSW-RTBURBONSA-N 0.000 claims description 2
PBALTVQMQFVDBV-GRTNUQQKSA-N (6s,10br)-6-(4-methylsulfanylphenyl)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline;perchloric acid Chemical compound OCl(=O)(=O)=O.C1=CC(SC)=CC=C1[C@H]1C2=CC=CC=C2[C@H]2CCCN2C1 PBALTVQMQFVDBV-GRTNUQQKSA-N 0.000 claims description 2
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 2
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 2
RTHCYVBBDHJXIQ-INIZCTEOSA-N (S)-fluoxetine Chemical compound O([C@@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-INIZCTEOSA-N 0.000 claims description 2
HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 claims description 2
QYXJWBDKQAIHJM-ZMPXXIOZSA-N (z)-but-2-enedioic acid;3-[(1s,2s)-2-[(dimethylamino)methyl]cyclopropyl]-1h-indole-5-carbonitrile Chemical compound OC(=O)\C=C/C(O)=O.CN(C)C[C@H]1C[C@@H]1C1=CNC2=CC=C(C#N)C=C12 QYXJWBDKQAIHJM-ZMPXXIOZSA-N 0.000 claims description 2
FDHOKMCJHQRFPP-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-n-phenylpyrazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)C(C(=O)NC=2C=CC=CC=2)=NN1C1=CC=CC=C1Cl FDHOKMCJHQRFPP-UHFFFAOYSA-N 0.000 claims description 2
WQOPKMNALJBALB-UHFFFAOYSA-N 1-[2-(4-fluorophenyl)-2-(4-methylpiperazin-1-yl)ethyl]-4-(4-naphthalen-1-ylbutyl)piperazine Chemical compound C1CN(C)CCN1C(C=1C=CC(F)=CC=1)CN1CCN(CCCCC=2C3=CC=CC=C3C=CC=2)CC1 WQOPKMNALJBALB-UHFFFAOYSA-N 0.000 claims description 2
QUSLYAPLTMMCFE-UHFFFAOYSA-N 1-[2-[4-(6-fluoro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-6-methylsulfonyl-3-propan-2-yl-4h-2$l^{6},1,3-benzothiadiazine 2,2-dioxide Chemical compound FC1=CC=C2C(C=3CCN(CC=3)CCN3C4=CC=C(C=C4CN(S3(=O)=O)C(C)C)S(C)(=O)=O)=CNC2=C1 QUSLYAPLTMMCFE-UHFFFAOYSA-N 0.000 claims description 2
TZZGTNZBLPCBIS-UHFFFAOYSA-N 1-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-methoxy-3,4-dihydroquinolin-2-one Chemical compound O=C1CCC=2C(OC)=CC=CC=2N1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 TZZGTNZBLPCBIS-UHFFFAOYSA-N 0.000 claims description 2
MHPMXTGKTXJIDI-IBGZPJMESA-N 2-(1-benzofuran-6-yl)-n-[[(1r)-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]methyl]-n-methylethanamine Chemical compound C1=C2C=COC2=CC(CCN(C)C[C@H]2C=3C=CC=C(C=3CCC2)OC)=C1 MHPMXTGKTXJIDI-IBGZPJMESA-N 0.000 claims description 2
YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims description 2
ZGNPLCMMVKCTHM-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[4-(2-methylphenyl)-6-morpholin-4-ylpyridin-3-yl]propanamide Chemical compound C=1N=C(N2CCOCC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ZGNPLCMMVKCTHM-UHFFFAOYSA-N 0.000 claims description 2
YNZFUWZUGRBMHL-UHFFFAOYSA-N 2-[4-[3-(11-benzo[b][1]benzazepinyl)propyl]-1-piperazinyl]ethanol Chemical compound C1CN(CCO)CCN1CCCN1C2=CC=CC=C2C=CC2=CC=CC=C21 YNZFUWZUGRBMHL-UHFFFAOYSA-N 0.000 claims description 2
LYXKFNHUJJDTIA-UHFFFAOYSA-N 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-1,1-dioxo-1,2-benzothiazol-3-one Chemical compound O=C1C2=CC=CC=C2S(=O)(=O)N1CCCCN(CC1)CCN1C1=CC(Cl)=CC2=C1OCCO2 LYXKFNHUJJDTIA-UHFFFAOYSA-N 0.000 claims description 2
FWYRGHMKHZXXQX-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-2-(dimethylamino)-2-methylpropan-1-ol Chemical compound CN(C)C(C)(CO)CC1=CC=C(Cl)C(Cl)=C1 FWYRGHMKHZXXQX-UHFFFAOYSA-N 0.000 claims description 2
QIWQQMZFTOCFGF-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-4-(3-methyl-4-methylsulfanylphenoxy)benzenesulfonamide Chemical compound C1=C(C)C(SC)=CC=C1OC1=CC=C(S(N)(=O)=O)C=C1CN(C)C QIWQQMZFTOCFGF-UHFFFAOYSA-N 0.000 claims description 2
SAURKKOJWIFYSR-UHFFFAOYSA-N 4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine;hydrate;hydrochloride Chemical compound O.Cl.N1=C2SC(C)=CC2=C(C=2C(=CC=CC=2)F)N=C1N1CCNCC1 SAURKKOJWIFYSR-UHFFFAOYSA-N 0.000 claims description 2
RYNSGDFWBJWWSZ-UHFFFAOYSA-N 4-[[6-methoxy-2-(4-methoxyphenyl)-3-benzofuranyl]-oxomethyl]benzonitrile Chemical compound C1=CC(OC)=CC=C1C1=C(C(=O)C=2C=CC(=CC=2)C#N)C2=CC=C(OC)C=C2O1 RYNSGDFWBJWWSZ-UHFFFAOYSA-N 0.000 claims description 2
MCNQUWLLXZZZAC-BJUDXGSMSA-N 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-n-piperidin-1-ylpyrazole-3-carboxamide Chemical compound C1=CC(O[11CH3])=CC=C1C1=C(C#N)C(C(=O)NN2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl MCNQUWLLXZZZAC-BJUDXGSMSA-N 0.000 claims description 2
QPGGEKPRGVJKQB-UHFFFAOYSA-N 5-[2-(dimethylamino)ethyl]-11-methyl-6-benzo[b][1,4]benzodiazepinone Chemical compound O=C1N(CCN(C)C)C2=CC=CC=C2N(C)C2=CC=CC=C21 QPGGEKPRGVJKQB-UHFFFAOYSA-N 0.000 claims description 2
GGDBEAVVGFNWIA-UHFFFAOYSA-N 6-nitro-2-(1-piperazinyl)quinoline Chemical compound C1=CC2=CC([N+](=O)[O-])=CC=C2N=C1N1CCNCC1 GGDBEAVVGFNWIA-UHFFFAOYSA-N 0.000 claims description 2
DAMJAPQYXVKRQY-CCTNCFKYSA-N 88086-41-3 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 DAMJAPQYXVKRQY-CCTNCFKYSA-N 0.000 claims description 2
BUZAJRPLUGXRAB-UHFFFAOYSA-N AM-251 Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(I)C=C1 BUZAJRPLUGXRAB-UHFFFAOYSA-N 0.000 claims description 2
WJVLEIDMFWNIAA-QEUVDIPISA-N C1=CC=CC2=CC([C@H]3C[C@@H]4CC[C@@H](N4C)[C@@H]3C(=O)CC)=CC=C21 Chemical compound C1=CC=CC2=CC([C@H]3C[C@@H]4CC[C@@H](N4C)[C@@H]3C(=O)CC)=CC=C21 WJVLEIDMFWNIAA-QEUVDIPISA-N 0.000 claims description 2
BJIPVHLRWSDKOS-UHFFFAOYSA-N LY-367,265 Chemical compound C1=2C3=CC=CC=2CCCN1S(=O)(=O)N3CCN(CC1)CC=C1C1=CNC2=CC(F)=CC=C21 BJIPVHLRWSDKOS-UHFFFAOYSA-N 0.000 claims description 2
UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims description 2
YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 claims description 2
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 2
KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims description 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 2
FZSPJBYOKQPKCD-VIFPVBQESA-N [1-(4-chlorophenyl)-2-methylpropan-2-yl] (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1 FZSPJBYOKQPKCD-VIFPVBQESA-N 0.000 claims description 2
JHOTYHDSLIUKCJ-UHFFFAOYSA-N [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-3-indolyl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C(C1=CC=C(I)C=C11)=C(C)N1CCN1CCOCC1 JHOTYHDSLIUKCJ-UHFFFAOYSA-N 0.000 claims description 2
ZCFHOMLAFTWDFM-UHFFFAOYSA-N a-796,260 Chemical compound CC1(C)C(C)(C)C1C(=O)C(C1=CC=CC=C11)=CN1CCN1CCOCC1 ZCFHOMLAFTWDFM-UHFFFAOYSA-N 0.000 claims description 2
229960003148 adinazolam Drugs 0.000 claims description 2
GJSLOMWRLALDCT-UHFFFAOYSA-N adinazolam Chemical compound C12=CC(Cl)=CC=C2N2C(CN(C)C)=NN=C2CN=C1C1=CC=CC=C1 GJSLOMWRLALDCT-UHFFFAOYSA-N 0.000 claims description 2
229960002629 agomelatine Drugs 0.000 claims description 2
YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 claims description 2
229960003225 alaproclate Drugs 0.000 claims description 2
229960000959 amineptine Drugs 0.000 claims description 2
VDPUXONTAVMIKZ-UHFFFAOYSA-N amineptine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2C([NH2+]CCCCCCC(=O)O)C2=CC=CC=C21 VDPUXONTAVMIKZ-UHFFFAOYSA-N 0.000 claims description 2
229950006529 befetupitant Drugs 0.000 claims description 2
IALVDLPLCLFBCF-CHWSQXEVSA-N befloxatone Chemical compound O=C1O[C@@H](COC)CN1C1=CC=C(OCC[C@@H](O)C(F)(F)F)C=C1 IALVDLPLCLFBCF-CHWSQXEVSA-N 0.000 claims description 2
229950000017 befloxatone Drugs 0.000 claims description 2
OFYVIGTWSQPCLF-NWDGAFQWSA-N bicifadine Chemical compound C1=CC(C)=CC=C1[C@@]1(CNC2)[C@H]2C1 OFYVIGTWSQPCLF-NWDGAFQWSA-N 0.000 claims description 2
229950010365 bicifadine Drugs 0.000 claims description 2
WZXHSWVDAYOFPE-UHFFFAOYSA-N brofaromine Chemical compound C=1C2=CC(OC)=CC(Br)=C2OC=1C1CCNCC1 WZXHSWVDAYOFPE-UHFFFAOYSA-N 0.000 claims description 2
229950004068 brofaromine Drugs 0.000 claims description 2
OLQJWCYRPYGTJI-UHFFFAOYSA-N bts 74,398 Chemical compound C=1C=C(Cl)C(Cl)=CC=1C1(C(=O)CSCCCN(CCN)CCN)CCC1 OLQJWCYRPYGTJI-UHFFFAOYSA-N 0.000 claims description 2
229960001058 bupropion Drugs 0.000 claims description 2
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 2
229960004301 butriptyline Drugs 0.000 claims description 2
ALELTFCQZDXAMQ-UHFFFAOYSA-N butriptyline Chemical compound C1CC2=CC=CC=C2C(CC(C)CN(C)C)C2=CC=CC=C21 ALELTFCQZDXAMQ-UHFFFAOYSA-N 0.000 claims description 2
150000001721 carbon Chemical group 0.000 claims description 2
229950000303 cericlamine Drugs 0.000 claims description 2
229950002663 clovoxamine Drugs 0.000 claims description 2
XXPVSQRPGBUFKM-SAPNQHFASA-N clovoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(Cl)C=C1 XXPVSQRPGBUFKM-SAPNQHFASA-N 0.000 claims description 2
PDIMOTRDGUQMNY-UHFFFAOYSA-N cx157 Chemical compound FC(F)(F)COC1=CC=C2S(=O)(=O)C3=CC=C(F)C=C3OC2=C1 PDIMOTRDGUQMNY-UHFFFAOYSA-N 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 claims description 2
229960005217 dapoxetine Drugs 0.000 claims description 2
SRPXSILJHWNFMK-MEDUHNTESA-N dasotraline Chemical compound C1([C@@H]2CC[C@H](C3=CC=CC=C32)N)=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-MEDUHNTESA-N 0.000 claims description 2
229960001623 desvenlafaxine Drugs 0.000 claims description 2
229960004597 dexfenfluramine Drugs 0.000 claims description 2
229960003075 dibenzepin Drugs 0.000 claims description 2
ZJDCGVDEEHWEIG-UHFFFAOYSA-N diclofensine Chemical compound C1N(C)CC2=CC(OC)=CC=C2C1C1=CC=C(Cl)C(Cl)=C1 ZJDCGVDEEHWEIG-UHFFFAOYSA-N 0.000 claims description 2
229950007329 diclofensine Drugs 0.000 claims description 2
229960001393 dosulepin Drugs 0.000 claims description 2
IQQBRKLVEALROM-UHFFFAOYSA-N drinabant Chemical compound C=1C(F)=CC(F)=CC=1N(S(=O)(=O)C)C(C1)CN1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 IQQBRKLVEALROM-UHFFFAOYSA-N 0.000 claims description 2
229960002866 duloxetine Drugs 0.000 claims description 2
229960004341 escitalopram Drugs 0.000 claims description 2
WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims description 2
OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 claims description 2
229950003930 femoxetine Drugs 0.000 claims description 2
229960000647 gepirone Drugs 0.000 claims description 2
QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 claims description 2
229960002844 iprindole Drugs 0.000 claims description 2
PLIGPBGDXASWPX-UHFFFAOYSA-N iprindole Chemical compound C1CCCCCC2=C1N(CCCN(C)C)C1=CC=CC=C12 PLIGPBGDXASWPX-UHFFFAOYSA-N 0.000 claims description 2
229950004138 litoxetine Drugs 0.000 claims description 2
MJJDYOLPMGIWND-UHFFFAOYSA-N litoxetine Chemical compound C=1C=C2C=CC=CC2=CC=1COC1CCNCC1 MJJDYOLPMGIWND-UHFFFAOYSA-N 0.000 claims description 2
229960002813 lofepramine Drugs 0.000 claims description 2
SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 claims description 2
HTODIQZHVCHVGM-JTQLQIEISA-N lubazodone Chemical compound C1=2CCCC=2C(F)=CC=C1OC[C@@H]1CNCCO1 HTODIQZHVCHVGM-JTQLQIEISA-N 0.000 claims description 2
229950004415 lubazodone Drugs 0.000 claims description 2
229960004090 maprotiline Drugs 0.000 claims description 2
QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims description 2
229960004794 melitracen Drugs 0.000 claims description 2
GWWLWDURRGNSRS-UHFFFAOYSA-N melitracen Chemical compound C1=CC=C2C(=CCCN(C)C)C3=CC=CC=C3C(C)(C)C2=C1 GWWLWDURRGNSRS-UHFFFAOYSA-N 0.000 claims description 2
229960003955 mianserin Drugs 0.000 claims description 2
229960000600 milnacipran Drugs 0.000 claims description 2
229960001785 mirtazapine Drugs 0.000 claims description 2
RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims description 2
229960004644 moclobemide Drugs 0.000 claims description 2
YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims description 2
229960001165 modafinil Drugs 0.000 claims description 2
229960001800 nefazodone Drugs 0.000 claims description 2
VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims description 2
229960001158 nortriptyline Drugs 0.000 claims description 2
FAHGZANUNVVDFL-HYBUGGRVSA-N omiloxetine Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](COC=2C=C3OCOC3=CC=2)CN(CC(=O)C=2C=CC(F)=CC=2)CC1 FAHGZANUNVVDFL-HYBUGGRVSA-N 0.000 claims description 2
229950005637 omiloxetine Drugs 0.000 claims description 2
229960005290 opipramol Drugs 0.000 claims description 2
LWRJZIPAGMGXQJ-DIJVWCDGSA-N org-6582 Chemical compound Cl.C1C2=CC(Cl)=CC=C2[C@@H]2[C@@H](N)[C@H]1C=CC2 LWRJZIPAGMGXQJ-DIJVWCDGSA-N 0.000 claims description 2
UNAZAADNBYXMIV-UHFFFAOYSA-N otenabant Chemical compound C1CC(NCC)(C(N)=O)CCN1C1=NC=NC2=C1N=C(C=1C(=CC=CC=1)Cl)N2C1=CC=C(Cl)C=C1 UNAZAADNBYXMIV-UHFFFAOYSA-N 0.000 claims description 2
FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 2
229960003089 pramipexole Drugs 0.000 claims description 2
229950003857 propizepine Drugs 0.000 claims description 2
YFLBETLXDPBWTD-UHFFFAOYSA-N propizepine Chemical compound O=C1N(CC(C)N(C)C)C2=CC=CC=C2NC2=NC=CC=C21 YFLBETLXDPBWTD-UHFFFAOYSA-N 0.000 claims description 2
URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 2
229960004431 quetiapine Drugs 0.000 claims description 2
229960000279 quinupramine Drugs 0.000 claims description 2
JCBQCKFFSPGEDY-UHFFFAOYSA-N quinupramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1C(C1)C2CCN1CC2 JCBQCKFFSPGEDY-UHFFFAOYSA-N 0.000 claims description 2
229960001150 ramelteon Drugs 0.000 claims description 2
229960000425 rizatriptan Drugs 0.000 claims description 2
TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 claims description 2
MQTUXRKNJYPMCG-CYBMUJFWSA-N robalzotan Chemical compound C1CCC1N([C@H]1COC=2C(F)=CC=C(C=2C1)C(=O)N)C1CCC1 MQTUXRKNJYPMCG-CYBMUJFWSA-N 0.000 claims description 2
229950003023 robalzotan Drugs 0.000 claims description 2
229950000366 roxindole Drugs 0.000 claims description 2
BKTTWZADZNUOBW-UHFFFAOYSA-N roxindole Chemical compound C=12[CH]C(O)=CC=C2N=CC=1CCCCN(CC=1)CCC=1C1=CC=CC=C1 BKTTWZADZNUOBW-UHFFFAOYSA-N 0.000 claims description 2
PJSUYRBCBFPCQW-UHFFFAOYSA-N sb-649,915 Chemical compound O1CC(=O)NC2=CC(CC3CCN(CC3)CCOC=3C4=CC=C(N=C4C=CC=3)C)=CC=C21 PJSUYRBCBFPCQW-UHFFFAOYSA-N 0.000 claims description 2
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 2
229960003946 selegiline Drugs 0.000 claims description 2
229960004425 sibutramine Drugs 0.000 claims description 2
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims description 2
229950003174 surinabant Drugs 0.000 claims description 2
229960004380 tramadol Drugs 0.000 claims description 2
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 2
IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 claims description 2
229960000438 udenafil Drugs 0.000 claims description 2
229960004688 venlafaxine Drugs 0.000 claims description 2
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 2
229960003740 vilazodone Drugs 0.000 claims description 2
SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 claims description 2
RPZBRGFNBNQSOP-UHFFFAOYSA-N vilazodone hydrochloride Chemical compound Cl.C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 RPZBRGFNBNQSOP-UHFFFAOYSA-N 0.000 claims description 2
229950002976 volinanserin Drugs 0.000 claims description 2
YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 claims description 2
DUYGSAPQVOBOCS-UHFFFAOYSA-N win 54,461 Chemical compound C1=CC(OC)=CC=C1C(=O)C(C1=CC=C(Br)C=C11)=C(C)N1CCN1CCOCC1 DUYGSAPQVOBOCS-UHFFFAOYSA-N 0.000 claims description 2
JMOBMHYQLPPCKP-UHFFFAOYSA-N win 56,098 Chemical compound CC1=C(C(=O)C=2C3=CC=CC=C3C=C3C=CC=CC3=2)C2=CC=CC=C2N1CCN1CCOCC1 JMOBMHYQLPPCKP-UHFFFAOYSA-N 0.000 claims description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
XRJQDZXKLCOTGV-DOFZRALJSA-N (5z,8z,11z,14z)-n,n-bis[(3-chloro-4-hydroxyphenyl)methyl]icosa-5,8,11,14-tetraenamide Chemical compound C=1C=C(O)C(Cl)=CC=1CN(C(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC)CC1=CC=C(O)C(Cl)=C1 XRJQDZXKLCOTGV-DOFZRALJSA-N 0.000 claims 1
125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
XUPZAARQDNSRJB-SJDTYFKWSA-N trans-dothiepin hydrochloride Chemical compound [Cl-].C1SC2=CC=CC=C2C(=C/CC[NH+](C)C)/C2=CC=CC=C21 XUPZAARQDNSRJB-SJDTYFKWSA-N 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 58
239000000543 intermediate Substances 0.000 abstract description 21
238000000034 method Methods 0.000 abstract description 16
238000003786 synthesis reaction Methods 0.000 abstract description 11
230000015572 biosynthetic process Effects 0.000 abstract description 8
230000001225 therapeutic effect Effects 0.000 abstract description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
239000000243 solution Substances 0.000 description 22
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
238000005160 1H NMR spectroscopy Methods 0.000 description 16
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
239000004615 ingredient Substances 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
239000003772 serotonin uptake inhibitor Substances 0.000 description 15
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 14
239000002904 solvent Substances 0.000 description 14
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 13
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
239000007787 solid Substances 0.000 description 12
101150041968 CDC13 gene Proteins 0.000 description 11
238000009472 formulation Methods 0.000 description 11
239000012044 organic layer Substances 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
241001465754 Metazoa Species 0.000 description 10
239000007832 Na2SO4 Substances 0.000 description 10
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
239000005557 antagonist Substances 0.000 description 10
201000010099 disease Diseases 0.000 description 10
229940079593 drug Drugs 0.000 description 10
229940093499 ethyl acetate Drugs 0.000 description 10
235000019439 ethyl acetate Nutrition 0.000 description 10
229910052938 sodium sulfate Inorganic materials 0.000 description 10
235000011152 sodium sulphate Nutrition 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
125000000217 alkyl group Chemical group 0.000 description 8
238000004440 column chromatography Methods 0.000 description 8
229940125904 compound 1 Drugs 0.000 description 8
229940126570 serotonin reuptake inhibitor Drugs 0.000 description 8
229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
235000017557 sodium bicarbonate Nutrition 0.000 description 8
229930003827 cannabinoid Natural products 0.000 description 7
239000003557 cannabinoid Substances 0.000 description 7
239000003153 chemical reaction reagent Substances 0.000 description 7
239000013078 crystal Substances 0.000 description 7
238000002844 melting Methods 0.000 description 7
230000008018 melting Effects 0.000 description 7
230000000144 pharmacologic effect Effects 0.000 description 7
229960000549 4-dimethylaminophenol Drugs 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
238000010168 coupling process Methods 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000007788 liquid Substances 0.000 description 6
230000003389 potentiating effect Effects 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000000047 product Substances 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
238000010992 reflux Methods 0.000 description 6
239000003826 tablet Substances 0.000 description 6
FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
239000002775 capsule Substances 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
238000001914 filtration Methods 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
125000006850 spacer group Chemical group 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
WYICVZCBFLADDG-UHFFFAOYSA-N 5-fluoro-3-(4-piperazin-1-ylbutyl)-1h-indole Chemical compound C12=CC(F)=CC=C2NC=C1CCCCN1CCNCC1 WYICVZCBFLADDG-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
241000282412 Homo Species 0.000 description 4
SOAXNJHXHXGWHW-UHFFFAOYSA-N [7,7-dimethoxy-7-[4-(trifluoromethyl)phenyl]heptyl] 4-methylbenzenesulfonate Chemical compound C=1C=C(C(F)(F)F)C=CC=1C(OC)(OC)CCCCCCOS(=O)(=O)C1=CC=C(C)C=C1 SOAXNJHXHXGWHW-UHFFFAOYSA-N 0.000 description 4
ZXQCTWWIUMZVMV-UHFFFAOYSA-N [7-oxo-7-[4-(trifluoromethyl)phenyl]heptyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCCCCCC(=O)C1=CC=C(C(F)(F)F)C=C1 ZXQCTWWIUMZVMV-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
238000013459 approach Methods 0.000 description 4
239000012267 brine Substances 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
229940125782 compound 2 Drugs 0.000 description 4
229940126214 compound 3 Drugs 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
239000011521 glass Substances 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
238000012552 review Methods 0.000 description 4
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
239000000725 suspension Substances 0.000 description 4
150000003512 tertiary amines Chemical class 0.000 description 4
238000004809 thin layer chromatography Methods 0.000 description 4
238000003260 vortexing Methods 0.000 description 4
GXCOERNENFJWMF-UHFFFAOYSA-N 1-(5-fluoro-1h-indol-3-yl)-4-piperazin-1-ylbutan-1-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(F)=CC=C2NC=C1C(=O)CCCN1CCNCC1 GXCOERNENFJWMF-UHFFFAOYSA-N 0.000 description 3
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
IEKNAZIQUGNFHK-UHFFFAOYSA-N 2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-n-[7-oxo-7-[4-(trifluoromethyl)phenyl]heptyl]imidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(CC)=C(C(=O)NCCCCCCC(=O)C=2C=CC(=CC=2)C(F)(F)F)N=C1C1=CC=CC=C1Cl IEKNAZIQUGNFHK-UHFFFAOYSA-N 0.000 description 3
GPNSGYCDYDXWRA-UHFFFAOYSA-N 4-chloro-1-(5-fluoro-1h-indol-3-yl)butan-1-one Chemical compound FC1=CC=C2NC=C(C(=O)CCCCl)C2=C1 GPNSGYCDYDXWRA-UHFFFAOYSA-N 0.000 description 3
ZUOBXCIPMDWWFZ-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-4-phenyl-3,4-dihydropyrazole-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=NN(C(=O)NS(=O)(=O)C=2C=CC(Cl)=CC=2)CC1C1=CC=CC=C1 ZUOBXCIPMDWWFZ-UHFFFAOYSA-N 0.000 description 3
MTLNBIXPEXQYSG-UHFFFAOYSA-N 7,7-dimethoxy-7-[4-(trifluoromethyl)phenyl]heptan-1-amine Chemical compound NCCCCCCC(OC)(OC)C1=CC=C(C(F)(F)F)C=C1 MTLNBIXPEXQYSG-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000003213 activating effect Effects 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000009260 cross reactivity Effects 0.000 description 3
239000012043 crude product Substances 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
239000003446 ligand Substances 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
238000002603 single-photon emission computed tomography Methods 0.000 description 3
150000005846 sugar alcohols Chemical class 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
YQSNUZSOAJSQBT-UHFFFAOYSA-N tert-butyl 4-[4-(5-fluoro-1h-indol-3-yl)-4-oxobutyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CCCC(=O)C1=CNC2=CC=C(F)C=C12 YQSNUZSOAJSQBT-UHFFFAOYSA-N 0.000 description 3
235000015112 vegetable and seed oil Nutrition 0.000 description 3
239000008158 vegetable oil Substances 0.000 description 3
QUFAKSWIQCYGTG-UHFFFAOYSA-N 1-(5-fluoro-1h-indol-3-yl)-4-piperazin-1-ylbutan-1-one Chemical compound C12=CC(F)=CC=C2NC=C1C(=O)CCCN1CCNCC1 QUFAKSWIQCYGTG-UHFFFAOYSA-N 0.000 description 2
KKGOLWWWLBHJRN-UHFFFAOYSA-N 2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethylimidazole-4-carboxylic acid Chemical compound C=1C=C(Cl)C=CC=1N1C(CC)=C(C(O)=O)N=C1C1=CC=CC=C1Cl KKGOLWWWLBHJRN-UHFFFAOYSA-N 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
CISDGPNUSAADJL-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-[7-(4-fluorophenyl)-7,7-dimethoxyheptyl]-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C=1C=C(F)C=CC=1C(OC)(OC)CCCCCCNC(N1N=C(C(C1)C=1C=CC=CC=1)C=1C=CC(Cl)=CC=1)=NS(=O)(=O)C1=CC=C(Cl)C=C1 CISDGPNUSAADJL-UHFFFAOYSA-N 0.000 description 2
BZEMLJWQRJJMFH-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-[7-(4-fluorophenyl)-7-oxoheptyl]-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1=CC(F)=CC=C1C(=O)CCCCCCNC(N1N=C(C(C1)C=1C=CC=CC=1)C=1C=CC(Cl)=CC=1)=NS(=O)(=O)C1=CC=C(Cl)C=C1 BZEMLJWQRJJMFH-UHFFFAOYSA-N 0.000 description 2
RUJFFKXKLUYXEN-UHFFFAOYSA-N 7-(oxan-2-yloxy)-1-[4-(trifluoromethyl)phenyl]heptan-1-one Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)CCCCCCOC1OCCCC1 RUJFFKXKLUYXEN-UHFFFAOYSA-N 0.000 description 2
QKKDVKUPBMXALS-UHFFFAOYSA-N 7-amino-1-[4-(trifluoromethyl)phenyl]heptan-1-one Chemical compound NCCCCCCC(=O)C1=CC=C(C(F)(F)F)C=C1 QKKDVKUPBMXALS-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
229920000945 Amylopectin Polymers 0.000 description 2
102000018208 Cannabinoid Receptor Human genes 0.000 description 2
108050007331 Cannabinoid receptor Proteins 0.000 description 2
229940126062 Compound A Drugs 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
241000792859 Enema Species 0.000 description 2
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
102000016979 Other receptors Human genes 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
239000012317 TBTU Substances 0.000 description 2
QLYKJCMUNUWAGO-GAJHUEQPSA-N Taranabant Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=C(C=CC=1)C#N)C(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 QLYKJCMUNUWAGO-GAJHUEQPSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000556 agonist Substances 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000003555 cannabinoid 1 receptor antagonist Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
150000005829 chemical entities Chemical class 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
235000013681 dietary sucrose Nutrition 0.000 description 2
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000007876 drug discovery Methods 0.000 description 2
230000008406 drug-drug interaction Effects 0.000 description 2
239000003480 eluent Substances 0.000 description 2
239000007920 enema Substances 0.000 description 2
229940095399 enema Drugs 0.000 description 2
ZDCXWLIGAGVMHP-UHFFFAOYSA-N ethyl 2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethylimidazole-4-carboxylate Chemical compound C=1C=C(Cl)C=CC=1N1C(CC)=C(C(=O)OCC)N=C1C1=CC=CC=C1Cl ZDCXWLIGAGVMHP-UHFFFAOYSA-N 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
150000002430 hydrocarbons Chemical group 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
229950008889 indatraline Drugs 0.000 description 2
SVFXPTLYMIXFRX-BBRMVZONSA-N indatraline Chemical compound C1([C@@H]2C[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 SVFXPTLYMIXFRX-BBRMVZONSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
239000008101 lactose Substances 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000013160 medical therapy Methods 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
JSJUKIJLGZOQAK-UHFFFAOYSA-N n'-[7-(2-aminoethoxyimino)-7-[4-(trifluoromethyl)phenyl]heptyl]-5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C=1C=C(C(F)(F)F)C=CC=1C(=NOCCN)CCCCCCNC(N1N=C(C(C1)C=1C=CC=CC=1)C=1C=CC(Cl)=CC=1)=NS(=O)(=O)C1=CC=C(Cl)C=C1 JSJUKIJLGZOQAK-UHFFFAOYSA-N 0.000 description 2
NSGWWVBXJVDWCD-UHFFFAOYSA-N n-[7-(2-aminoethoxyimino)-7-[4-(trifluoromethyl)phenyl]heptyl]-2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(CC)=C(C(=O)NCCCCCCC(=NOCCN)C=2C=CC(=CC=2)C(F)(F)F)N=C1C1=CC=CC=C1Cl NSGWWVBXJVDWCD-UHFFFAOYSA-N 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
229910000069 nitrogen hydride Inorganic materials 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
239000012038 nucleophile Substances 0.000 description 2
VAWHTWXBNQFBAJ-UHFFFAOYSA-N o-(2-aminoethyl)hydroxylamine;dihydrochloride Chemical compound Cl.Cl.NCCON VAWHTWXBNQFBAJ-UHFFFAOYSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
230000003285 pharmacodynamic effect Effects 0.000 description 2
CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 2
229910000343 potassium bisulfate Inorganic materials 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
229960001866 silicon dioxide Drugs 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
CMIBUZBMZCBCAT-HZPDHXFCSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HZPDHXFCSA-N 0.000 description 1
125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
FTNJQNQLEGKTGD-ZFJHNFROSA-N 1,3-benzodioxole Chemical group C1O[13C]=2[13CH]=[13CH][13CH]=[13CH][13C]=2O1 FTNJQNQLEGKTGD-ZFJHNFROSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
BNGPVKSKKYIJCR-UHFFFAOYSA-N 2-chloro-1,3-dimethylimidazolidine;hydrochloride Chemical compound [Cl-].CN1CC[NH+](C)C1Cl BNGPVKSKKYIJCR-UHFFFAOYSA-N 0.000 description 1
MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
DRNJIKRLQJRKMM-UHFFFAOYSA-N 4-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=C(C#N)C=C1 DRNJIKRLQJRKMM-UHFFFAOYSA-N 0.000 description 1
CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 1
ODFFPRGJZRXNHZ-UHFFFAOYSA-N 5-fluoroindole Chemical compound FC1=CC=C2NC=CC2=C1 ODFFPRGJZRXNHZ-UHFFFAOYSA-N 0.000 description 1
125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
OILAJDYBLIPBTR-UHFFFAOYSA-N 7-hydroxy-1-[4-(trifluoromethyl)phenyl]heptan-1-one Chemical compound OCCCCCCC(=O)C1=CC=C(C(F)(F)F)C=C1 OILAJDYBLIPBTR-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
101100154577 Arabidopsis thaliana NTR1 gene Proteins 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
102100033868 Cannabinoid receptor 1 Human genes 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
244000020551 Helianthus annuus Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
240000004760 Pimpinella anisum Species 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
238000001237 Raman spectrum Methods 0.000 description 1
101710150104 Sensory rhodopsin-1 Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000862969 Stella Species 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
JNZSIEDOCQMVKM-UHFFFAOYSA-N [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethylimidazol-4-yl]-[4-[4-(5-fluoro-1h-indol-3-yl)butyl]piperazin-1-yl]methanone Chemical compound C=1C=C(Cl)C=CC=1N1C(CC)=C(C(=O)N2CCN(CCCCC=3C4=CC(F)=CC=C4NC=3)CC2)N=C1C1=CC=CC=C1Cl JNZSIEDOCQMVKM-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000011949 advanced processing technology Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000001769 aryl amino group Chemical group 0.000 description 1
125000005129 aryl carbonyl group Chemical group 0.000 description 1
125000002393 azetidinyl group Chemical group 0.000 description 1
125000003828 azulenyl group Chemical group 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
239000012965 benzophenone Substances 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
239000012867 bioactive agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
229940010415 calcium hydride Drugs 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
239000012320 chlorinating reagent Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000006310 cycloalkyl amino group Chemical group 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
CKQQMPJQZXIYMJ-UHFFFAOYSA-N dihydrate;dihydrochloride Chemical compound O.O.Cl.Cl CKQQMPJQZXIYMJ-UHFFFAOYSA-N 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
150000002081 enamines Chemical class 0.000 description 1
239000002621 endocannabinoid Substances 0.000 description 1
235000004626 essential fatty acids Nutrition 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
229940060367 inert ingredients Drugs 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
230000007794 irritation Effects 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
239000010410 layer Substances 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000005259 measurement Methods 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000009251 neurologic dysfunction Effects 0.000 description 1
230000007658 neurological function Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000005429 oxyalkyl group Chemical group 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
238000012856 packing Methods 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000002265 phtalazinyl group Chemical group 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000002985 plastic film Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229940044519 poloxamer 188 Drugs 0.000 description 1
238000002600 positron emission tomography Methods 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
235000015320 potassium carbonate Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000000634 powder X-ray diffraction Methods 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000452 restraining effect Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
230000007017 scission Effects 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000011343 solid material Substances 0.000 description 1
238000000279 solid-state nuclear magnetic resonance spectrum Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000008685 targeting Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000004001 thioalkyl group Chemical group 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
125000005490 tosylate group Chemical group 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 1
125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000008648 triflates Chemical class 0.000 description 1
JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1